

University of Arkansas for Medical Sciences receives \$2.2 million grant to study efferocytosis in retinopathy

[Martin David Harp](#)

September 23rd 2024

Efferocytosis' role in retinopathy is largely unknown despite knowledge of the process in other diseases.



The sights of Stockholm

[Sydney M Crago](#)

September 23rd 2024

A look back at the 2024 ASRS conference held in Sweden



Higher molar dose in the real world and clinical trials

[Hattie Hayes](#)

September 23rd 2024


Pearls from PULSAR, PHOTON, and working practitioners

Stealth BioTherapeutics presents Advertisement preclinical data on bevemipretide's retinal delivery in AMD models

[Martin David Harp](#)

September 23rd 2024





The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.



EURETINA 2024: The Vit-Buckle Society makes its EURETINA debut

[Hattie Hayes](#)

September 22nd 2024

Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.

Faster identification of infants at high risk of rop by evaluating the effects of maternal and fetal vascular malperfusion

[Lynda Charters](#)

September 22nd 2024

Iris freckles: Potential biomarker for AMD

[Lynda Charters](#)

September 22nd 2024

Advertisement

X

EURETINA 2024: Factors predictive of macular edema development in patients with silicone oil tamponade

Lynda Charters

September 22nd 2024

Additional previous surgeries and the duration of the SO tamponade had little or no impact

EMA announces positive opinion for SB15 (OPUVIZ, Samsung Bioepis and Biogen)

Hattie Hayes

September 21st 2024

The CHMP will recommend SB15, biosimilar to aflibercept (Eylea), for marketing authorisation by the European Commission

EURETINA 2024: Yousif Subhi, MD, PhD, on the "things that matter" in macular degeneration and central serous chorioretinopathy

Martin David Harp; Sydney M Crago

September 21st 2024

Yousif Subhi, MD, PhD, delivered the Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC."

Advertisement



EURETINA 2024: Andrea Govetto, MD, PhD, says it takes teamwork to understand macular edema

[Hattie Hayes](#)

September 21st 2024

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

Spotlight on GA: Promoting early detection and treatment

[Lynda Charters](#)

September 21st 2024

EURETINA 2024: Phase 1 HELIOS trial for OTX-TKI

[Hattie Hayes](#); [Martin David Harp](#); [Sydney M Crago](#)

September 20th 2024

Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.

Advertisement

EURETINA 2024: Unraveling the genetic spectrum of combined retinal

dystrophy and hearing impairment

[Lynda Charters](#)

September 20th 2024

Researchers in Portugal investigated Usher syndrome, Senior-Loker syndrome and other ciliopathies

EURETINA 2024: Ricardo Leitão Guerra, MD, MSc, FICO, speaks about multimodal imaging

[Hattie Hayes](#); [Martin David Harp](#)

September 20th 2024

Why having a set process for diagnostic imaging is crucial to patient outcomes

The unique role of the retina optometrist

[Betty Zhang, OD](#)

September 20th 2024

Zhang's journey as the first retina optometrist in Colorado

EURETINA 2024: Subretinal gene therapy improves function and structure in patients with Bothnia Dystrophy

[Lynda Charters](#)

September 19th 2024



Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

EURETINA 2024: Ocular involvement among patients with COVID-19 infection or vaccination

[Lynda Charters](#)

September 19th 2024

A case series illuminates neuro-ophthalmologic manifestations, retinal vascular involvement and other pathologies

Opthea completes process performance qualification (PPQ)

[Sydney M Crago](#)

September 19th 2024

The PPQ campaign consisted of the production of 3 successful consecutive commercial-scale drug substance batches required for the validation of Opthea's manufacturing process.

Alkeus Pharmaceuticals shares results of SAGA study of oral gildeuretinol acetate for GA

[Sydney M Crago](#)



September 19th 2024

Oral gildeuretinol demonstrated a clinically meaningful reduction in the GA lesion growth rate at 24 months in the SAGA study.

EURETINA 2024: Cardio-ocular syndrome and retinal microvasculature changes in acute heart failure

[Lynda Charters](#)

September 19th 2024

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

EURETINA 2024: Efficacy results and patient preference findings from the Pagoda trial

[Hattie Hayes](#)

September 19th 2024

Dr Margaret A. Chang shares data on the port delivery system with ranibizumab, and her strategy for making the most of conferences

Advertisement

4DMT shares data from Phase 1/2 PRISM clinical trial, 4FRONT Phase 3 study design



[Sydney M Crago](#)

September 18th 2024

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Opthea makes changes to leadership and hires senior roles

[Sydney M Crago](#)

September 18th 2024

Opthea Limited has made changes to the company's executive leadership in its and notable hires in senior roles.

OCT-based AI analysis brings changes in GA and therapeutic responses into sharp focus

[Lynda Charters](#)

September 18th 2024

Atsena Therapeutics receives Orphan Drug Designation from FDA for ATSN-201 gene therapy to treat X-linked retinoschisis

[David Hutton](#)

September 17th 2024



The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

ANI Pharmaceuticals completes acquisition of Alimera Sciences

David Hutton

September 17th 2024

The acquisition strengthens the company's rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ophthalmology.

The current state of gene therapy in managing neovascular macular degeneration

Veeral Sheth, MD, MBA, FAS, FASRS

September 17th 2024

Gene therapy offers a promising alternative by potentially providing long-lasting effects from a single treatment.

The future of retina care

Marta Stevanovic, MD, MSc

September 17th 2024



Retina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.

Social factors associated with diabetic retinopathy visit adherence

Arash Delavar, MD, MPH; Amer Fadel Alsoudi, MD; Asad Loya, MD; Christina Y. Weng, MD, MBA

September 16th 2024

1	2	3	4	5	6	7	8	...	73	>
---	---	---	---	---	---	---	---	-----	----	---

Advertisement



Contact Info

[About](#)

[Advertise](#)

[Contact Us](#)

[Terms and
Conditions](#)

[Privacy](#)

[Do Not Sell
My Personal
Information](#)



2
Commerce
Drive
Cranbury,
NJ 08512



609-716-
7777

© 2024 MJH Life Sciences

All rights reserved.

Advertisement



Advertisement

News > All ▾




Protecting vision during the 2024 solar eclipse

[David Hutton](#)

March 22nd 2024

Viewing the solar eclipse without proper eye protection can pose hazards, and ophthalmologists can educate patients about the importance of using certified solar viewing glasses or other safe viewing methods.




Ophthalmology Foundation elects new board members and officers

[David Hutton](#)

March 22nd 2024

New members bring a wealth of experience and expertise from various sectors within the ophthalmology,


pharmaceutical, and healthcare fields, further strengthening the Ophthalmology Foundation's mission.



Ocular injuries after motor vehicle accidents: Long-term effects on quality of life

Lynda Charters

March 21st 2024



Topical drop treatment for full-thickness macular hole closure

Lynda Charters

March 20th 2024

Wang and colleagues conducted a retrospective case series patients with full-thickness macular holes.




Projections show anticipated rapid expansion of retinal vein occlusion market

Sydney M Crago

March 20th 2024

Research estimates that the RVO market will see a compound annual growth rate of 11.9%.



Clinical trials: What to keep in mind

Peter J. McDonnell, MD

March 20th 2024

With 37 years of clinical trial experience, Peter J. McDonnell, MD, offer some tips.




Advanced retinoblastoma characterized by low expression of NR1D1 and NR2E3

Lynda Charters

March 19th 2024

The investigators explained that the survival rate of patients with retinoblastoma has improved significantly as a result of intra-arterial chemotherapy and enucleation surgery.



Key takeaways from the DAVIO 2 study with Rishi Singh, MD

Sydney M Crago

March 19th 2024

After 3 loading doses, the patients were randomly assigned to receive EYP-1901 or continue to receive aflibercept at 8



Modern Retina™
from **Ophthalmology**



**Why wait? The data show
administering steroids to DME patients**



with good vision leads to long-term success

Daniel F. Kiernan, MD, FACS

March 19th 2024

A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.



ISS National Lab-sponsored study to test a novel gene therapy for AMD

David Hutton

March 18th 2024

An investigation is set to launch on SpaceX's 30th Commercial Resupply Services mission to the International Space Station contracted by NASA to test the therapy in space.



New dawn of GA management requires renewed attention to imaging

Jeremiah Brown Jr, MD

March 18th 2024

It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).